ArticleTherapeutics and clinical risk management2005
Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.
Article in Therapeutics and clinical risk management, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients.The Journal of antimicrobial chemotherapy · 2019Pooled it
- Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers.European journal of clinical pharmacology · 2012Trial
- New Cannabinoids and Chlorin-Type Metabolites from the Flowers ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Effects ofMicroRNA (Shariqah, United Arab Emirates) · 2024Article
- Pilot Study: Personalized Medicine in Endoscopy, Can Pharmacogenomics Predict Response to Conscious Sedation?Journal of personalized medicine · 2023Article
- Pharmacogenetic Testing in a 70-Year-Old Woman with Polypharmacy and Multiple Comorbidities: A Case Report.The American journal of case reports · 2023Article
- Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice.Antibiotics (Basel, Switzerland) · 2022Review
- Identification of miR-199a-5p, miR-214-3p and miR-99b-5p as Fibrosis-Specific Extracellular Biomarkers and Promoters of HSC Activation.International journal of molecular sciences · 2021Article
- Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.Croatian medical journal · 2020Review
- Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention.British journal of clinical pharmacology · 2020Article
- Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System.ACS medicinal chemistry letters · 2015Article
- Phenotype standardization for statin-induced myotoxicity.Clinical pharmacology and therapeutics · 2014Article
- A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis.Infectious diseases and therapy · 2013Article
- Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management.Therapeutics and clinical risk management · 2013Article
- Modeling chemical interaction profiles: I. Spectral data-activity relationship and structure-activity relationship models for inhibitors and non-inhibitors of cytochrome P450 CYP3A4 and CYP2D6 isozymes.Molecules (Basel, Switzerland) · 2012Article
- Drug interactions with herbal medicines.Clinical pharmacokinetics · 2012Review
- The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mechanism-based inhibition of cytochrome P450 (CYP) 3A4 is characterized by NADPH-, time-, and concentration-dependent enzyme inactivation, occurring when some drugs are converted by CYPs to reactive metabolites. Such inhibition of CYP3A4 can be due to the chemical modification of the heme, the protein, or both as a result of covalent binding of modified heme to the protein. The inactivation of CYP3A4 by drugs has important clinical significance as it metabolizes approximately 60% of therapeutic drugs, and its inhibition frequently causes unfavorable drug-drug interactions and toxicity. The clinical outcomes due to CYP3A4 inactivation depend on many factors associated with the enzyme, drugs, and patients. Clinical professionals should adopt proper approaches when using drugs that are mechanism-based CYP3A4 inhibitors. These include early identification of drugs behaving as CYP3A4 inactivators, rational use of such drugs (eg, safe drug combination regimen, dose adjustment, or discontinuation of therapy when toxic drug interactions occur), therapeutic drug monitoring, and predicting the risks for potential drug-drug interactions. A good understanding of CYP3A4 inactivation and proper clinical management are needed by clinical professionals when these drugs are used.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.